Cytokinetics Inc. Stock
Price
Target price
€62.52
€62.52
-1.820%
-1.16
-1.820%
€81.13
17:31 / Tradegate
WKN: A1W1KK / Symbol: CYTK / Name: Cytokinetics / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cytokinetics Inc. Stock
A loss of -1.820% shows a downward development for Cytokinetics Inc..
The stock is an absolute favorite of our community with 47 Buy predictions and no Sell predictions.
As a result the target price of 81 € shows a positive potential of 29.56% compared to the current price of 62.52 € for Cytokinetics Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Cytokinetics Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Cytokinetics Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cytokinetics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cytokinetics Inc. | -1.820% | -10.031% | -11.825% | 101.519% | 19.028% | 110.861% | 129.065% |
| Heron Therapeutics Inc. | 2.340% | -32.607% | -20.601% | -75.641% | -73.914% | -80.497% | -96.899% |
| Evolus Inc | -0.400% | 27.435% | 22.133% | 31.811% | 28.183% | -21.506% | -21.506% |
| Rhythm Pharmaceuticals | -0.990% | 6.878% | 7.447% | 24.691% | 8.021% | 313.934% | 763.248% |
Comments
Cytokinetics (CYTK) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (CYTK) had its price target raised by JPMorgan Chase & Co. from $97.00 to $103.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (CYTK) had its "overweight" rating reaffirmed by Barclays PLC.
Show more
Ratings data for CYTK provided by MarketBeat
News
Cytokinetics Q2 Earnings Call Highlights
Key Points
- Interested in Cytokinetics, Incorporated? Here are five stocks we like better.
- MYQORZO’s U.S. launch is gaining traction: The drug reached 1,500 dispensed patients and more than 700
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%
Robert I. Blum, president & CEO of Cytokinetics, Incorporated (NASDAQ:CYTK), reported a sale of 7,500 shares of common stock on July 13, 2026, according to an SEC Form 4 filing.
Transaction value
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise
Key Points
- Interested in Cytokinetics, Incorporated? Here are five stocks we like better.
- MYKORZO’s launch is outperforming expectations, with Cytokinetics saying early prescriptions